IDYA

29.58

1.40% -0.42

Handel nachbörslich: 29.50 -0.08 -0.27%

Ideaya Biosciences Inc (IDYA)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$30.00

Offen:

$29.36

24-Stunden-Volumen:

1.12M

Relative Volume:

1.62

Marktkapitalisierung:

$2.45B

Einnahmen:

$23.38M

Nettoeinkommen (Verlust:

$-155.22M

KGV:

-20.40

EPS:

-1.45

Netto-Cashflow:

$-134.36M

1W Leistung:

-0.94%

1M Leistung:

-1.30%

6M Leistung:

-29.87%

1J Leistung:

+2.14%

1-Tages-Spanne:

$28.33

$29.59

1-Wochen-Bereich:

$27.52

$30.50

52-Wochen-Spanne:

$27.52

$47.73

Ideaya Biosciences Inc Stock (IDYA) Company Profile

Firmenname

Ideaya Biosciences Inc

Sektor

Healthcare (1181)

Branche

Biotechnology (671)

Telefon

650-443-6209

Adresse

7000 SHORELINE CT, SUITE 350, SOUTH SAN FRANCISCO, CA

Mitarbeiter

124

Twitter

Nächster Verdiensttermin

2024-11-05

Neueste SEC-Einreichungen

IDYA's Discussions on Twitter

Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-08-08	Eingeleitet	SVB Securities	Outperform
2023-05-24	Eingeleitet	Goldman	Buy
2023-04-24	Hochstufung	Stifel	Hold → Buy
2023-03-23	Eingeleitet	Berenberg	Buy
2023-02-28	Eingeleitet	RBC Capital Mkts	Outperform
2022-12-28	Eingeleitet	CapitalOne	Overweight
2022-10-27	Eingeleitet	Citigroup	Buy
2022-08-15	Herabstufung	Stifel	Buy → Hold
2022-07-18	Fortgesetzt	Oppenheimer	Outperform
2022-03-10	Hochstufung	Stifel	Hold → Buy
2021-09-23	Eingeleitet	Stifel	Hold
2021-06-04	Fortgesetzt	Robert W. Baird	Outperform
2021-03-11	Eingeleitet	Guggenheim	Buy
2020-10-07	Eingeleitet	Wedbush	Outperform
2020-09-01	Eingeleitet	Northland Capital	Outperform
2020-07-13	Hochstufung	JP Morgan	Neutral → Overweight
2020-06-17	Bestätigt	H.C. Wainwright	Buy
2020-04-06	Eingeleitet	H.C. Wainwright	Buy
2020-03-13	Eingeleitet	ROTH Capital	Buy
2019-10-17	Eingeleitet	Oppenheimer	Outperform
2019-09-10	Eingeleitet	Robert W. Baird	Outperform
2019-06-17	Eingeleitet	Citigroup	Buy
2019-06-17	Eingeleitet	JP Morgan	Neutral
2019-06-17	Eingeleitet	Jefferies	Buy

Alle ansehen

Ideaya Biosciences Inc Aktie (IDYA) Neueste Nachrichten

03:06 AM

IDEAYA Biosciences (NASDAQ:IDYA) Shares Down 4.5%Here's What Happened - MarketBeat

03:06 AM

08:38 AM

IDEAYA Biosciences (NASDAQ:IDYA) Releases Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat

08:38 AM

Leerink Partners Downgrades IDEAYA Biosciences (NASDAQ:IDYA) to Market Perform - MarketBeat

08:38 AM

01:11 AM

Wedbush Reiterates "Outperform" Rating for IDEAYA Biosciences (NASDAQ:IDYA) - MarketBeat

01:11 AM

Nov 04, 2024

IDEAYA Biosciences: Q3 2024 Financial and Clinical Progress - TipRanks

Nov 04, 2024

/C O R R E C T I O N -- IDEAYA Biosciences, Inc./ - Yahoo Finance

Nov 04, 2024

IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update - PR Newswire

Nov 04, 2024

Nov 03, 2024

abrdn plc Buys Shares of 232,830 IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat

Nov 03, 2024

Nov 01, 2024

Ideaya Biosciences stock hits 52-week low at $28.04 By Investing.com - Investing.com South Africa

Nov 01, 2024

IDEAYA Biosciences (NASDAQ:IDYA) Reaches New 1-Year LowHere's What Happened - MarketBeat

Nov 01, 2024

Ideaya Biosciences stock hits 52-week low at $28.04 - Investing.com

Nov 01, 2024

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - StockTitan

Nov 01, 2024

Oct 30, 2024

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinic - GuruFocus.com

Oct 30, 2024

Oct 29, 2024

Earnings Preview: IDEAYA Biosciences, Inc. (IDYA) Q3 Earnings Expected to Decline - MSN

Oct 29, 2024

IDEAYA Biosciences' (IDYA) "Outperform" Rating Reaffirmed at Oppenheimer - MarketBeat

Oct 29, 2024

Oct 28, 2024

IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors - The Malaysian Reserve

Oct 28, 2024

IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors – Company Announcement - Financial Times

Oct 28, 2024

IDEAYA Biosciences Announces IND-Clearance for Werner Helicase D - GuruFocus.com

Oct 28, 2024

IDEAYA Biosciences Reports Encouraging Clinical Data for IDE397 in MTAP-Deletion Urothelial Cancer and NSCLC - Defense World

Oct 28, 2024

Oct 27, 2024

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives $55.45 Average Price Target from Brokerages - MarketBeat

Oct 27, 2024

Oct 25, 2024

IDYAIDEAYA Biosciences, Inc. Latest Stock News & Market Updates - StockTitan

Oct 25, 2024

IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024 - Quantisnow

Oct 25, 2024

Oct 24, 2024

Cantor Fitzgerald Initiates Coverage on IDEAYA Biosciences (NASDAQ:IDYA) - Defense World

Oct 17, 2024

Oct 16, 2024

Investor’s Delight: Ideaya Biosciences Inc (IDYA) Closes Strong at 30.82, Up 1.15 - The Dwinnex

Oct 16, 2024

Cantor Fitzgerald initiates coverage on Ideaya Biosciences shares with Overweight rating - Investing.com Canada

Oct 16, 2024

Oct 15, 2024

IDEAYA Biosciences (NASDAQ:IDYA) Now Covered by Analysts at Cantor Fitzgerald - MarketBeat

Oct 15, 2024

Oct 14, 2024